帕拉泰克制药（纳斯达克股票代码：PRTK）获得StockNews.com分析师的持有评级

StockNews.com assumed coverage on shares of Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) in a research note published on Thursday. The firm issued a hold rating on the specialty pharmaceutical company's stock.

Paratek Pharmaceuticals Trading Up 4.1 %

Shares of NASDAQ:PRTK opened at $1.54 on Thursday. The firm has a market cap of $85.55 million, a PE ratio of -1.31 and a beta of 1.52. The company has a fifty day simple moving average of $2.00 and a 200 day simple moving average of $2.29. Paratek Pharmaceuticals has a 12-month low of $1.29 and a 12-month high of $3.65.

Insider Transactions at Paratek Pharmaceuticals

In other news, Chairman Michael Bigham sold 15,750 shares of the stock in a transaction dated Wednesday, December 21st. The shares were sold at an average price of $1.99, for a total transaction of $31,342.50. Following the transaction, the chairman now owns 1,209,702 shares of the company's stock, valued at $2,407,306.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Paratek Pharmaceuticals news, Chairman Michael Bigham sold 15,750 shares of the business's stock in a transaction on Wednesday, December 21st. The shares were sold at an average price of $1.99, for a total transaction of $31,342.50. Following the completion of the sale, the chairman now owns 1,209,702 shares in the company, valued at $2,407,306.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Evan Loh sold 23,489 shares of the business's stock in a transaction that occurred on Wednesday, December 21st. The shares were sold at an average price of $1.99, for a total value of $46,743.11. Following the transaction, the chief executive officer now owns 1,208,198 shares of the company's stock, valued at approximately $2,404,314.02. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,996 shares of company stock valued at $118,762. Insiders own 8.00% of the company's stock.

Institutional Trading of Paratek Pharmaceuticals

Large investors have recently modified their holdings of the company. Prospera Financial Services Inc grew its position in Paratek Pharmaceuticals by 156.8% in the 3rd quarter. Prospera Financial Services Inc now owns 11,465 shares of the specialty pharmaceutical company's stock worth $29,000 after purchasing an additional 7,000 shares during the last quarter. SG Americas Securities LLC bought a new position in Paratek Pharmaceuticals in the 2nd quarter worth approximately $26,000. Jane Street Group LLC bought a new position in Paratek Pharmaceuticals in the 3rd quarter worth approximately $36,000. Arete Wealth Advisors LLC acquired a new stake in Paratek Pharmaceuticals in the 4th quarter valued at approximately $26,273,500,000. Finally, CI Private Wealth LLC bought a new stake in Paratek Pharmaceuticals during the 4th quarter valued at $29,000. Institutional investors and hedge funds own 41.90% of the company's stock.

About Paratek Pharmaceuticals

(Get Rating)

Paratek Pharmaceuticals, Inc engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections.

Featured Stories

• Get a free copy of the StockNews.com research report on Paratek Pharmaceuticals (PRTK)
• MarketBeat Week in Review – 3/13 – 3/17
• This Small Tech With Big Growth Prospects Is Nearing A Buy Point
• Don't Chase FedEx Higher, Wait For The Pullback
• 3 Stocks For A Defensive Tech Portfolio
• Milk the Dividends on These 3 Cash Cows

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.